Floatz logo

Irinotecan

Pediatric Solid Tumors

Washington University School of MedicineSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Pediatric Solid Tumors cohort.

Asset / SponsorPhaseRating
Sorafenib
Washington University School of Medicine
Phase 2CCC
Carboplatin
Bristol-Myers Squibb
Phase 1/2CCC
Temsirolimus
Memorial Sloan Kettering Cancer Center
Phase 1CC
Perifosine
Memorial Sloan Kettering Cancer Center
Phase 1CC

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →